Real-World Utilization, Barriers, and Factors Associated With the Targeted Treatment of Metastatic Colorectal Cancer Patients in China: A Multi-Center, Hospital-Based Survey Study

被引:2
作者
Liu, Yin [1 ]
Zhang, Xi [2 ]
Xu, Hui-Fang [1 ]
Shi, Ji-Hai [3 ]
Zhao, Yu-Qian [4 ]
Du, Ling-Bin [5 ]
Liu, Yun-Yong [6 ]
Wang, Wen-Jun [7 ]
Cao, He-Lu [8 ]
Ma, Li [9 ]
Huang, Juan-Xiu [10 ]
Cao, Ji [11 ]
Li, Li [12 ]
Fan, Yan-Ping [13 ]
Gu, Xiao-Fen [14 ]
Feng, Chang-Yan [15 ]
Zhu, Qian [16 ]
Wang, Xiao-Hui [17 ]
Du, Jing-Chang [18 ]
Zhang, Jian-Gong [1 ]
Zhang, Shao-Kai [1 ]
Qiao, You-Lin [1 ,19 ]
机构
[1] Zhengzhou Univ, Henan Engn Res Ctr Canc Prevent & Control, Affiliated Canc Hosp,Henan Canc Hosp, Dept Canc Epidemiol,Henan Int Joint Lab Canc Prev, Zhengzhou, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing Off Canc Prevent & Control, Beijing, Peoples R China
[3] Baotou Med Coll, Affiliated Hosp 1, Clin Epidemiol Res Ctr, Dept Dermatol, Baotou, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Canc Prevent, Canc Hosp, Hangzhou, Peoples R China
[6] China Med Univ, Liaoning Canc Hosp & Inst, Liaoning Off Canc Control & Res, Canc Hosp, Shenyang, Peoples R China
[7] Jining Med Univ, Sch Nursing, Jining, Peoples R China
[8] Xinxiang Cent Hosp, Dept Prevent Hlth, Xinxiang, Peoples R China
[9] Dalian Med Univ, Publ Hlth Sch, Dalian, Peoples R China
[10] Wuzhou Red Cross Hosp, Dept Gastroenterol, Wuzhou, Peoples R China
[11] Guangxi Med Univ, Affiliated Hosp 1, Dept Canc Prevent & Control Off, Nanning, Guangxi, Peoples R China
[12] Jinan Univ, Affiliated Hosp 1, Dept Clin Res, Guangzhou, Peoples R China
[13] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
[14] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Student Affairs, Urumqi, Xinjiang, Peoples R China
[15] Chongqing Univ, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China
[16] Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China
[17] Gansu Prov Canc Hosp, Dept Publ Hlth, Lanzhou, Peoples R China
[18] Chengdu Med Coll, Sch Publ Hlth, Chengdu, Peoples R China
[19] Chinese Acad Med Sci & Peking Union Med Coll, Ctr Global Hlth, Sch Populat Med & Publ Hlth, Beijing, Peoples R China
关键词
associated factors; utilization; barriers; metastatic colorectal cancer; targeted treatment; COST-EFFECTIVENESS ANALYSIS; RISK-FACTORS; FRUQUINTINIB; BEVACIZUMAB; REGORAFENIB; THERAPY; OXALIPLATIN; MANAGEMENT; SURVIVAL; PLACEBO;
D O I
10.3389/ijph.2023.1606091
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: To explore the utilization, barriers, and factors associated with the targeted treatment of Chinese metastatic colorectal cancer (mCRC) patients.Methods: A total of 1,688 mCRC patients from 19 hospitals in 14 cities were enrolled from March 2020 to March 2021 using stratified, multistage cluster sampling. The use of targeted therapy and any barriers patients experienced were collected. Logistic regression analyses were conducted to identify the factors associated with initiating targeted treatment.Results: About 51.6% of the patients initiated targeted therapy, of whom 44.5%, 20.2%, and 35.2% started first-, second-, and third-line treatment, respectively. The most reported barriers were high medical costs and a lack of belief in the efficacy of targeted therapy. Patients treated in the general hospital, diagnosed at an older age, less educated, and who had a lower family income, no medical insurance, poor health-related quality of life, metastasis outside the liver/lung or systemic metastasis, a shorter duration of mCRC were less likely to initiate targeted therapy.Conclusion: Reduced medical costs and interventional education to improve public awareness could facilitate the use of targeted treatment for mCRC.
引用
收藏
页数:11
相关论文
共 41 条
  • [1] Aday L A, 1974, Health Serv Res, V9, P208
  • [2] Andersen RM, 2008, MED CARE, V46, P647, DOI [10.1097/MLR.0b013e31817a835d, 10.1097/MLR.0b013e31817f4d48]
  • [3] [Anonymous], 2008, Clinical Practice Guidelines in Oncology - v1.2008
  • [4] Global patterns and trends in colorectal cancer incidence and mortality
    Arnold, Melina
    Sierra, Monica S.
    Laversanne, Mathieu
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    Bray, Freddie
    [J]. GUT, 2017, 66 (04) : 683 - 691
  • [5] Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
    Bai, Liangliang
    Zhang, Pengfei
    Zhou, Kexun
    Liao, Weiting
    Li, Qiu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10419 - 10426
  • [6] The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
    Cao, De-Dong
    Xu, Hui-Lin
    Xu, Xi-Ming
    Ge, Wei
    [J]. ONCOTARGET, 2017, 8 (32) : 53631 - 53641
  • [7] Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
    Chen, Eric X.
    Jonker, Derek J.
    Loree, Jonathan M.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice C.
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Chris J.
    [J]. JAMA ONCOLOGY, 2020, 6 (06) : 831 - 838
  • [8] Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
    Chen, Jianxin
    Wang, Junhui
    Lin, Hai
    Peng, Yonghai
    [J]. MEDICAL SCIENCE MONITOR, 2019, 25 : 9179 - 9191
  • [9] Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review
    Chibaudel, Benoist
    Tournigand, Christophe
    Bonnetain, Franck
    Richa, Hubert
    Benetkiewicz, Magdalena
    Andre, Thierry
    de Gramont, Aimery
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (03) : 153 - 169
  • [10] Regorafenib: A Review in Metastatic Colorectal Cancer
    Dhillon, Sohita
    [J]. DRUGS, 2018, 78 (11) : 1133 - 1144